BioXcel Report Results of BXCL501 in P-Ib/II RELEASE Study for the Treatment of Opioid Withdrawal Symptoms
Shots:
- The P-Ib/II POC- RELEASE study involves assessing BXCL50 (130/ 60 /90 /120 /180 and 240 mcg- bid- ~ 12 hrs apart- 7 days treatment) vs PBO- following discontinuation of morphine maintenance in 125 patients with opioid use disorder who are physically dependent on opioids
- The study met its 1EPs and 2EPs in multiple dose cohort demonstrated numerically improvement in retention rates- rate of retention in 120mcg and 180mcg showed 42% and 52% vs 24% @Day 6 and was well tolerated
- The data from multiple dosing regimen has the potential to support the investigation across additional indications and treatment settings
Ref: GlobeNewswire | Image: Linkedin
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com